Диссертация (1139999), страница 19
Текст из файла (страница 19)
J. Psychiatry, 1996. - Vol. 30(Suppl.). - P. 68-75.67.Kessler, R. C. P., Chiu, W. T. a M., Jin, R. M. a, Ruscio, A. M. P., Shear, K.M. D., & Walters, E. E. M. S. The Epidemiology of Panic Attacks, Panic Disorder, andAgoraphobia in the National Comorbidity Survey Replication // Archives of GeneralPsychiatry April, 2006. – Vol.63. - № 4. – Р. 415–424.68.Klein D. F. The treatment of atypical depression // Eur. Psychiat., 1993, Vol.8, № 5, p. 251 – 255.69.Klein, D.
F. Delineation of two drug-responsive anxiety syndromes //Psychopharmacologia, 1964. – Vol.5. - № 6. – Р. 397–408.70.Klerman G. L., Weissman M. M., Ouellette R., Johnson J., Greenwald S.,Panic attacks in the community: Social morbidity and health care utilization // JAMA. –1991. – Vol. 265. - № 6. – P.742-746.71.Kranzler H.R., Tinsley J.A. Dual diagnosis and treatment: substance abuseand comorbid medical and psychiatric disorder, 2nd edition.
New York: Marcel Dekker,Inc. – P. 261-316.72.Kushner M.G., Beitman B.D. Panic attack without fear: an overview //Behav. Res. Ther., 1990 - V. 28. - №6. - P. 469-479.73.Lauria-Horner B. A., Pohl R. B. Pregabalin: a new anxiolytic // Expert OpinInvestig Drags, 2003. Vol. 12. № 4. Р. 663-672.74.Lesch K. R., Bengel D., Fleils A. et al.
Association of anxiety related traitswith a polymorphysm in the serotonin transporter gene regulatory region // Science, 1996,Vol. 274. - Р. 1483-1487.75.Lesch K. R., Greenberg B. D., Bennett A. et al. Serotonin transporter,personality and behaviour: toward dissection of gene-gene and gene-environmentinteraction/Molecular Geneties and Human Personality. - J. Benjamin, R. Ebstein, R. H.Belmaker (eds), APR Washington, D. C., 2002. - Р. 109-135.10876.Lesch K.
R., Mossner P. Genetically driven variation of serotonin uptake: isthere a link to affective spectrum, neurodevelopmental and neurodegenerative disorders?// Biol. Psychiatry, 1998. - Vol. 44, P. 179-192.77.Liebowitz M.R., Klein D.F. Hysteroid dysphoria. // Psychiat. Clin. America,1979.
- №2.- Р. 555—575.78.Liebowitz M.R., Quitkin F.M., Stewart J.W., et al. Antidepressant specificityin atypical depression// Arch. Gen. Psychiat. 1988. - Vol.45. - Р. 129-137.79.Lopez-Ibor Anxiety and Depression: Relevance ofor Clinical tudies. In: NewPharmacological Approaches to the Therapy of Depressive Disorders. – 1992. – P. 119130.80.Lum M., Fontaine R., Elie R., Ontiveros A. Divalproex sodium's antipaniceffect in panic disorder: A placebo-controlled study // Biol Psychiatry, 1990.-27:164A–165A.81.MacKinnon, D. F., Zandi, P. P., Cooper, J., Potash, J.
B., Simpson, S. G.,Gershon, E., DePaulo, J. R. Comorbid bipolar disorder and panic disorder in families witha high prevalence of bipolar disorder American Journal of Psychiatry, 2002. – Vol.159(1). P. 30–35.82.Mandalos G.E., Szarek B.L. New-oneset panic attacks in a patient treatedwith olanzapinie (letter) // J. Clin. Psychopharmacol, 1999. - №19. Р. 191.83.Masdrakis V. G., Papadimitriou G. N., Oulis P. Lamotrigini administrationin panic disorder with agoraphobia // Clin.
Neuropharmacol. 2010. – Vol. 33. - № 3. -Р126-128.84.Menaster M. Efficacy of quetiapine in panic disorder with agoraphobia andobsessive-compulsive disorder in patient with bipolar disorder // Psychiatry (Edgmont),2005. – Vol. 2. № 9. Р. 17-18.85.Nemiah, J. С Dissociation, conversion, and somatization, in AmericanPsychiatric Press Review of Psychiatry / J. С Nemiah / eds. A. Tasman, S.M. Goldfinger.- Washington: American Psychiatric Press, 1991. - Vol.
10. - P. 248—260.10986.Neumeister A., Nugent A.C., Waldeck T. et al. Neural and behavioralresponses to tryptophan depletion in unmedicated patients with remitted major depressivedisorder and controls // Arch. Gen. Psychiatry, 2004.- Vol.61 - Р. 765-773.87.Nutt D.J., Ballenger J.C. Anxiety disorders. Blackwell Pablishing, Oxford,2003, 542 Р.88.Onteveros A., Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder // J. Psychiatry Neurosci, 1992. – Vol. 17. - №2.
-Р. 78-80.89.Parker G., Parker K., Mitchell P. et al. Atypical depression: Australian andUS studies in accord // Curr. Opin. Psychiatry. - 2005. - Vol. 18, N 1. - P. 1-5.90.Parker G., Roy K., Mitchell P. et al. Atypical depression: a reappraisal // Am.J. Psychiatry. - 2002. - Vol. 159, N 9. - P. 1470 -1479.91.Parker G.B., Thase M.E. Atypical depression: a valid subtype? // J. Clin.Psychiatry.
- 2007, Mar. - Vol. 68, N 3. - P. 18-2292.Paykel E.S., Parker R.R., Rowan P.R. et al. Nosology of atypical depression// Psychol. Med. - 1983. - Vol. 13. - P. 131-139.93.Polack M.H., Simon N.M., Worthington J.J. et al. Combined paroxetine andclonazepam treatment strategies compared to paroxetine monotherapy for panic disorder// J. Psychopharmacol.,2003. – Vol. 17.
- № 3. Р. 276-282.94.Ravaris C.L., Nies A., Robinson D.S. et al. A multiple-dose controlled studyof phenelzine in depressive-anxiety states // Arch. Gen. Psychiatry. - 1976. - Vol. 33. - P.347-350.95.Ravaris C.L., Robinson D.S., Ives J.O. et al. Phenelzine and Amitriptyline inthe Treatment of Depression // Arch. Gen. Psychiatry. - 1980. - Vol. 37, № 9. - P. 10751080.96.Rowan P.R., Paykel E.S., Parker R.R.
Phenelzine and amitriptyline: effectson symptoms of neurotic depression // Br. J. Psychiatry. - 1982. - Vol. 140. - P. 475-483.97.Sargant W. Drugs in the treatment of depression // BMJ. - 1961. - Vol. 1. -P. 225-227.98.Sargant W. Some newer drugs in the treatment of depression and theirrelation to other somatic treatments // Psychosomatics.
- 1960. - Vol. 1. - P. 14-17.11099.Serretti A., Chiesa A., Calati R., et al. Novel antidepressants and panicdisorder: evidence beyond current guidelines // Neuropsychobiology. – 2011. – Vol. 63.- № 1. – Р.1-7.100. Smeraldi E., Diaferia G., Erzegovosi S. et al. Tryptophan depletion inobsessive-compulsive patients. // Biol. Psychiatry, 1996, Vol. 40, p. 398-402.101. Spila B., Szumi∤∤o A. [Gabapentin (GBP) in panic disorders - case report].[Article in Polish] // Psychiatr Pol. – 2006.- 40(6). P.
1061-1068.102. Stein D. J., Hollander E. Textbook of anxiety disorders. - Wasington, DC,APP, 2002. - Р. 515.103. Steketee G., Chambless D.L., Tran G.Q. Effects of axis I and II comorbidityon behavior therapy outcome for obsessive-compulsive disorder and agoraphobia //Compr. Psychiatry. 2001. – Vol.
42. - №1. Р. 76-86.104. Tyrer P. General neurotic syndrome and mixed anxiety-depression disorder// Classification of Neurosis. Tyrer P. (ed.) New York, Wiley, 1989. - P.132-164.105. Wang H. R., Woo Y. S. and Bahk W.-M. The potential role of atypicalantipsychotics in the treatment of panic disorder // Human Psychopharmacology: Clinicaland Experimental. -Vol. 29. - №5, Р. 405–413.106. West E.D., Dally P.J. Effects of iproniazid in depressive syndromes // Br.Med. J. - 1959. - Vol. 1. - P. 1491-1494.107. Westenberg H.
G. M., Den Boer J. A. The neuropharmacology of anxiety: areview of the role of serotonin // Handbook of Depression and Anxiety: A BiologicalApproach. - den Boer J. A., Ad Sitsen J. M. (eds.). New York, Marcel Dekker, 1994. - P.405-446.108. Wittchen H.-U., Hofler M., Merikandas K. Toward the identification of corepsychopathological process? // Arch. Gen. Psychiat. – 1999. - Vol. 59. - P. 929-931.109. Woodman C. L., Noye R.Jr.
Panic disorder: treatment with valproate // J.Clin. Psychiatry. - 1994. - № 55. – Р. 134-136.110. Zisook S., Shuchter S.R., Gallagher T. Atypical depression in an outpatientpsychiatric population // Depression. - 1993. - Vol. 1. - P. 268-274..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
